Aktis Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aktis Oncology, Inc. (AKTS) on January 12, 2026. The filing documents corporate governance changes executed in connection with the completion of the Company's initial public offering (IPO) on the same date. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and governance amendments rather than financial performance data.
Material Changes
The Company filed an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws effective immediately prior to the completion of the IPO. Key changes include:
- Capital Structure: Authorization of 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock.
- Preferred Stock: Elimination of all references to previously existing preferred stock series; authorization of 10,000,000 shares of undesignated preferred stock for future issuance.
- Board Governance: Establishment of a classified Board structure where directors serve staggered terms until the third annual meeting following their election.
- Director Removal: Requirement of at least two-thirds of voting shares to remove a director for cause.
- Stockholder Action: Elimination of the ability for stockholders to take action by written consent in lieu of a meeting.
- Bylaws: New procedures for stockholder proposals, director nominations, and modified indemnification provisions for directors and officers.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The document serves strictly to disclose the amendments to the Company's charter and bylaws.
Key Facts for Investor Verification
- Confirm the exact number of shares issued and outstanding following the IPO completion on January 12, 2026.
- Verify the specific terms of the newly authorized undesignated preferred stock series.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for detailed governance provisions.
- Check subsequent filings for the Company's first audited financial statements and cash position post-IPO.